GlassScriptPhysician profile
Theodore Affue
NPI 1386674000
$9,548.79
in general payments reported to CMS, 2019-2025
30 companies · $1,349 in 2025
The $1,349 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,849 · 2020: $237 · 2021: $811 · 2022: $553 · 2023: $972 · 2024: $1,778 · 2025: $1,349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,450 · Education: $368 · Travel and Lodging: $281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,449.89 |
| Education | $367.98 |
| Travel and Lodging | $280.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,151.53 | 2019-2024 | |
| Astellas Pharma US INC | $1,167.28 | 2019-2025 | Xtandi, Padcev, Myrbetriq |
| Teleflex LLC | $1,060.59 | 2022-2025 | Urolift, Barrigel |
| Bayer Healthcare Pharmaceuticals INC. | $844.57 | 2019-2025 | |
| Janssen Biotech, INC. | $566.94 | 2019-2025 | Erleada, Rybrevant, Carvykti |
| Sumitomo Pharma America, INC. | $405.05 | 2023-2025 | Gemtesa, Orgovyx |
| Neotract INC. | $330.84 | 2019-2020 | |
| Myovant Sciences INC. | $271.89 | 2021-2022 | |
| Boston Scientific Corporation | $236.67 | 2019-2023 | Rezum Generator |
| Endo Pharmaceuticals INC. | $220.16 | 2021-2024 | Xiaflex |
| Biotissue Holdings INC. | $167.71 | 2023 | |
| Pfizer INC. | $155.66 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $103.00 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $100.00 | 2019 | |
| Urogen Pharma, INC. | $76.12 | 2023-2025 | Jelmyto |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo USA, INC. | $75.78 | 2024-2025 | Xiaflex |
| Abbvie INC. | $68.63 | 2023-2025 | Botox |
| Ferring Pharmaceuticals INC. | $67.15 | 2019-2025 | Adstiladrin |
| Axonics, INC. | $64.53 | 2023-2024 | Axonics |
| Urovant Sciences INC | $60.73 | 2021-2022 | |
| Smith+Nephew, INC. | $54.62 | 2019-2020 | |
| Halozyme INC | $51.59 | 2023 | |
| Alnylam Pharmaceuticals INC. | $50.76 | 2021-2025 | Oxlumo |
| Coloplast Corp | $38.97 | 2023-2025 | Titan |
| Olympus America INC. | $35.44 | 2022-2024 | Itind System |
| Myriad Genetic Laboratories, INC. | $32.11 | 2023-2025 | Prolaris, Myrisk |
| Bk Medical Holding Company INC. | $25.68 | 2019 | |
| Foundation Medicine, INC. | $24.07 | 2023 | |
| Dentsply Ih INC. | $21.33 | 2021 | |
| Laborie Medical Technologies Corp. | $19.39 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Affue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.